Company Filing History:
Years Active: 2015
Title: The Innovations of Qinghai Peng: Pioneering Anti Notch-1 Antibodies
Introduction
Qinghai Peng, a dedicated inventor based in Del Mar, California, has made significant strides in the biomedical field. He is known for his invention of monoclonal antibodies that target Notch1, a crucial protein involved in various cell signaling pathways.
Latest Patents
Qinghai Peng holds a patent for Anti Notch-1 antibodies, which specifically bind to Notch1. This innovative invention encompasses antibodies that target at least two different epitopes, with one being located within the LinA domain and the other within the HD-C domain of the Notch1 negative regulatory region (NRR). This unique approach highlights the potential for advancements in therapeutic applications.
Career Highlights
Qinghai Peng is currently affiliated with Pfizer Corporation, a leading global biopharmaceutical company. His contributions to the field of biomedical research have positioned him as a noteworthy inventor, significantly impacting the development of novel therapies targeting critical biomarkers.
Collaborations
In his professional journey, Qinghai has collaborated with esteemed colleagues, including Kang Li and Ping Wei. These collaborations underscore the collective efforts within research teams to push the boundaries of scientific innovation and therapeutic development.
Conclusion
Qinghai Peng's innovative work in the realm of Anti Notch-1 antibodies reflects the promising future of targeted therapies in medicine. As he continues his endeavors at Pfizer Corporation, his contributions may pave the way for groundbreaking advancements in treating conditions tied to Notch1 signaling pathways.